Table 2.
Patient clinical and pathologic characteristics in the retrospective cohort
| Variables | Total (%) |
|---|---|
| No patients (%) | 22 (100) |
| Age, year, median (IQR) | 60 (57–66) |
| Pre-operative PSA (ng/mL), median (IQR) | 6.9 (4.8–16.1) |
| Pathologic Gleason score, n (%) | |
| ≤7 | 2 (9.1) |
| 8 | 9 (40.9) |
| ≥9 | 11 (50.0) |
| Unknown | 0 (0) |
| Pathologic stage, n (%) | |
| T2 | 3 (13.6) |
| T3a | 8 (36.4) |
| T3b | 10 (45.5) |
| T4 | 1 (4.5) |
| Positive surgical margins, n (%) | 12 (54.5) |
| Lymph node invasion, n (%) | 22 (100) |
| Follow-up time (censored), mo, median (IQR) | 16 (4–35) |
Abbreviations: IQR, interquartile range; mo, months; PSA, prostate-specific antigen; yr, year.